Mar 03, 2021 / 09:30AM GMT
Operator
Good day, ladies and gentlemen, and welcome to the Allergy Therapeutics Interim Results 2021. (Operator Instructions) I will now hand over to CEO, Manuel Llobet, to open the presentation. Please go ahead, sir.
Manuel Llobet - Allergy Therapeutics plc - CEO & Executive Director
Good morning, and many thanks for joining us today for Allergy Therapeutics interim results for the first 6 months ended 31st December 2020.
We appreciate, as always, everyone's continued flexibility with virtual meetings. And we very much hope that soon, we will be back with you all, conducting these events face-to-face.
Joining me here is Nick Wykeman's, Allergy's Chief Financial Officer; and Alan Bullimore, Allergy's Head of Innovation.
Moving on to Slide #2, which is the previous ones you have seen before. We begin proceedings, and I will quickly bring your attention to standard disclaimer slide, which is included in this presentation for completeness.
And so on to today's presentation, and Slide 3, please.
And here, you can find the
Half Year 2021 Allergy Therapeutics PLC Earnings Call Transcript
Mar 04, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers